IPHA logo

IPHA
Innate Pharma

1,481
Mkt Cap
$123.95M
Volume
9,264.00
52W High
$2.63
52W Low
$1.17
PE Ratio
-2.15
IPHA Fundamentals
Price
$1.32
Prev Close
$1.36
Open
$1.41
50D MA
$1.43
Beta
0.54
Avg. Volume
29,895.67
EPS (Annual)
-$0.6195
P/B
-4.85
Rev/Employee
$19,296.61
$143.00
Loading...
Loading...
News
all
press releases
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its business update and consolidated financial results for the quarter ending March 31...
Business Wire·1d ago
News Placeholder
More News
News Placeholder
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
Regulatory News: Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) releases its...
Business Wire·2d ago
News Placeholder
Innate Pharma (IPHA) Expected to Announce Quarterly Earnings on Wednesday
Innate Pharma (NASDAQ:IPHA) will be releasing its Q1 2026 TU earnings before the market opens on Wednesday, May 13. (View Earnings Report at...
MarketBeat·8d ago
News Placeholder
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announces that the Company will hold a conference call on Wednesday, May 13, 2026 at 1:30 p.m. CEST / 7:30 a.m. EDT, to provide an update on business progress for the first quarter of 2026...
Business Wire·8d ago
News Placeholder
Innate Pharma (NASDAQ:IPHA) Shares Down 0.7% - Here's What Happened
Innate Pharma (NASDAQ:IPHA) Stock Price Down 0.7% - Here's Why...
MarketBeat·9d ago
News Placeholder
Innate Pharma to Participate in the D. Boral Capital Global Conference
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in one-on-one investor meetings at the following...
Business Wire·21d ago
News Placeholder
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination...
Business Wire·26d ago
News Placeholder
Innate Pharma (OTCMKTS:IPHYF) Stock Price Up 9.3% - Here's What Happened
Innate Pharma (OTCMKTS:IPHYF) Stock Price Up 9.3% - Time to Buy...
MarketBeat·29d ago
News Placeholder
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
Regulatory News: Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General...
Business Wire·1mo ago
News Placeholder
HC Wainwright Decreases Earnings Estimates for Innate Pharma
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Free Report) - Stock analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for shares of Innate Pharma in a report released on Tuesday, April 7th. HC Wainwright analyst S. Ramakanth now anticipates that the company will po...
MarketBeat·1mo ago
<
1
2
...
>

Latest IPHA News

View
Top Discussions